A Phase IIb, Open Label, Single Arm, Multicenter Study to Evaluate the Effect of 48-weeks PEG-Interferon Alfa-2a (PEG-IFN) Administration on Serum HBsAg in Chronic Hepatitis B, HBeAg-Negative, Genotype D Patients on Treatment With Nucleos(t)Ide Analogues (NAs), Showing Stable HBV DNA Suppression
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Adefovir dipivoxil; Entecavir; Lamivudine; Tenofovir
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms HERMES
- Sponsors Roche
- 17 Apr 2016 Final results presented at The International Liver Congress™ 2016
- 02 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Feb 2015 Planned End Date changed from 1 Oct 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.